Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
UNIVERSITE CLAUDE BERNARD - LYON 1 has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 examiners and 5 art units, showing a fully distributed examination profile across the available record.
ARMSTRONG, JONATHAN D is the busiest examiner, with 1 pending matter. No single examiner has a larger recorded concentration, so counsel should avoid treating one prosecution approach as representative of the portfolio. Each matter warrants independent review of its claims, cited art, and amendment history.
The assignment pattern makes coordination especially important. Portfolio tracking can still identify recurring biotechnology issues, but responses should remain tailored to each art unit. Consistent claim terminology and a shared disclosure strategy may help preserve coherence while accommodating examiner-specific objections.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMSTRONG, JONATHAN D | 1 | 55.3% | +3.5% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +47.5% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +54.0% |
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 31d overdue |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 5d |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 31d overdue |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 5d |
| 17040246 | METHOD FOR REPROGRAMMING SOMATIC CELLS | BERTOGLIO, VALARIE E | 12d |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | — |
| Art Unit | Apps |
|---|---|
| 3645 | 1 |
| 1699 | 1 |
| 1682 | 1 |
| 1758 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18853607 | METHOD AND APPARATUS FOR ULTRASONIC EVALUATION OF AN ISOLATED ORGAN | ARMSTRONG, JONATHAN D | 3645 | §103 | Final Rejection | 76d | Pending | Oct 02, 2024 |
| 18038385 | RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS | SITTON, JEHANNE SOUAYA | 1699 | §101§112 | Non-Final OA | — | Pending | May 23, 2023 |
| 18035239 | USE OF TORQUE TENO VIRUS (TTV) AS A MARKER TO DETERMINE THE PROLIFERATIVE CAPACITY OF T LYMPHOCYTES | SWITZER, JULIET CAROLINE | 1682 | §101§103 | Final Rejection | 31d overdue | Pending | May 03, 2023 |
| 17766155 | METHOD FOR DETERMINING AN INDIVIDUAL ABILITY TO RESPOND TO A STIMULUS | FRITCHMAN, REBECCA M | 1758 | §103§112 | Non-Final OA | 5d | Pending | Apr 01, 2022 |
| 17040246 | METHOD FOR REPROGRAMMING SOMATIC CELLS | BERTOGLIO, VALARIE E | 1632 | §112 | Non-Final OA | 12d | Pending | Sep 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE CLAUDE BERNARD - LYON 1 has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Jonathan D Armstrong has the most, with 1 of UNIVERSITE CLAUDE BERNARD - LYON 1's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
